FFF enterprises
Helping Healthcare Care®

Respiratory Vaccines & Monoclonal Antibodies

Reference Chart

Choice - Multiple presentations from top manufacturers.
Confidence - Dependable deliveries to meet your patients' needs.
Commitment - Aligned with manufacturers' estimated shipping commitments.
Safety - Guaranteed Channel Integrity® ensures safe, reliable products for your patients.

PATIENT SAFETY • PRODUCT EFFICACY • FAIR PRICING

FFFenterprises.com | BioSupply.FFFenterprises.com | (800) 843-7477

Reference Chart

RESPIRATORY VACCINE

Influenza Vaccine Products & Dosage

Product Name	Manufacturer	Size	Age Group	Thimerosal Content	Doses	Route	Code*
Trivalent Vaccines							
FluMist®	AstraZeneca	0.2 mL PFS nasal spray 10-bx	2 to 49 yrs	Preservative-free	1 or 2[1]	Intranasal	90660
Fluad®	CSL Seqirus	0.5 mL PFS 10-bx	≥65 yrs	Preservative-free	1	Intramuscular[2]	90653
Flucelvax®	CSL Seqirus	0.5 mL PFS 10-bx	≥6 mo	Preservative-free	1 or 2[1]	Intramuscular[2]	90661
FLULAVAL®	GSK	0.5 mL PFS 10-bx	≥6 mo	Preservative-free	1 or 2[1]	Intramuscular[2]	90656
FLUARIX®	GSK	0.5 mL PFS 10-bx	≥6 mo	Preservative-free	1 or 2[1]	Intramuscular[2]	90656
mFLUSIVA™	Moderna US, Inc.	0.38 mL PFS 10-bx	≥50 yrs	Preservative-free	1	Intramuscular[2]	90616
Fluzone®	Sanofi	5 mL MDV	≥6 mo	25 mcg/dose	1	Intramuscular[2]	90658
Fluzone®	Sanofi	0.5 mL PFS 10-bx	≥6 mo	Preservative-free	1 or 2[1]	Intramuscular[2]	90656
Fluzone® High-Dose	Sanofi	0.5 mL PFS 10-bx	≥65 yrs	Preservative-free	1 or 2[1]	Intramuscular[2]	90662
Flublok®	Sanofi	0.5 mL PFS 10-bx	≥9 yrs	Preservative-free	1	Intramuscular[2]	90673

** Providers and payers should verify all codes for accuracy. Some influenza vaccines may not be available to all customers. Please contact your FFF Sales Representative to confirm your eligibility.*

The World Health Organization recommends that trivalent vaccines for use in the 2026-2027 influenza season in the northern hemisphere contain the following:

Egg-based vaccines
- an A/Missouri/11/2025 (H1N1)pdm09-like virus;
- an A/Darwin/1454/2025 (H3N2)-like virus; and
- a B/Tokyo/EIS13-175/2025 (B/Victoria lineage)-like virus.

Cell culture-, recombinant protein- or nucleic acid-based vaccines
- an A/Missouri/11/2025 (H1N1)pdm09-like virus;
- an A/Darwin/1415/2025 (H3N2)-like virus; and
- a B/Pennsylvania/14/2025 (B/Victoria lineage)-like virus.

The components were recommended on 27 February 2026.
https://www.who.int/news/item/27-02-2026-recommendations-for-influenza-vaccine-composition-for-the-2026-2027-northern-hemisphere-season

[1] Children aged 6 months through 8 years who are receiving influenza vaccine for the first time, and some in this age group who have previously been vaccinated, require two doses of vaccine administered at least 4 weeks apart. One or two doses depends on vaccination history as per Advisory Committee on Immunization Practices annual recommendations on prevention and control of influenza with vaccines.

[2] For adults and older children, the recommended site of vaccination is the deltoid muscle. The preferred site for infants and young children is the anterolateral aspect of the thigh.

COVID-19 Vaccine Products & Dosage

Product Name	Manufacturer	Size	Age Group	Vaccine Platform	Doses	Route	Code*
PEMGARDA®	Invivyd, Inc.	500 mg/4 mL SDV 1-ctn	≥12 yrs	mRNA	1	Intravenous	Q0224
mNEXSPIKE®	Moderna US, Inc.	0.2 mL PFS 10-bx	≥65 yrs; 12 to 64 yrs high risk	mRNA	1	Intramuscular	91321
SPIKEVAX®	Moderna US, Inc.	0.25 mL PFS 10-pk	6 mo to 11 yrs	mRNA	1	Intramuscular	91321
SPIKEVAX®	Moderna US, Inc.	0.5 mL PFS 10-bx	≥12 yrs	mRNA	1	Intramuscular	91322
COMIRNATY®	Pfizer-BioNTech	0.3 mL PFS 10-bx	≥65 yrs; 5 to 64 yrs high risk	mRNA	1	Intramuscular	91320
Nuvaxovid™	Sanofi	0.5 mL PFS 10-bx	≥65 yrs; 12 to 64 yrs high risk	Adjuvanted	1	Intramuscular	91304

Respiratory Syncytial Virus Products & Dosage

Product Name	Manufacturer	Size	Age Group	Doses	Route	Code*
AREXVY	GSK	0.5 mL SDV 10-bx	≥60 yrs; 50 to 59 yrs high risk	1	Intramuscular	90679
ENFLONSIA™	Merck	0.7 mL PFS 10-bx	Newborn up to 12 mo	1 or 2	Intramuscular[3]	90382
mRESVIA®	Moderna US, Inc.	0.5 mL PFS 2-bx	≥60 yrs; 18 to 59 yrs high risk	1	Intramuscular	90683
mRESVIA®	Moderna US, Inc.	0.5 mL PFS 10-bx	≥60 yrs; 18 to 59 yrs high risk	1	Intramuscular	90683
ABRYSVO®	Pfizer	0.5 mL PFS 1-bx	≥60 yrs; 18 to 59 yrs high risk Pregnant persons 32 to 36 wks gestation	1	Intramuscular	90678
ABRYSVO®	Pfizer	0.5 mL PFS 10-bx	≥60 yrs; 18 to 59 yrs high risk Pregnant persons 32 to 36 wks gestation	1	Intramuscular	90678
Beyfortus®	Sanofi	0.5 mL PFS 5-bx	Newborn up to 24 mo	1	Intramuscular	90380
Beyfortus®	Sanofi	1 mL PFS 5-bx	Newborn up to 24 mo	1	Intramuscular	90381

** Providers and payers should verify all codes for accuracy.*

[3] The preferred site for infants and young children is the anterolateral aspect of the thigh.

COMPLIMENTARY RESOURCES

FFF Enterprises supports healthcare providers with educational resources designed to enhance patient care and clinical decision-making. Through our secure Guaranteed Channel Integrity® supply chain and nationwide team of experts, we provide trusted support, product knowledge, and access to tools that help providers navigate treatment, reimbursement, and patient education.

*Available in multiple languages to reflect your community's diversity.

Connect with our U.S.-based Wow! Customer Care™ team at **(800) 843-7477** for personalized support.

Order FREE resource materials

Order FREE vaccine resources

FFF enterprises
Helping Healthcare Care®

Full prescribing information available on BioSupply.

Search by product name to learn more.

Emergency Ordering 24/7

FFFenterprises.com | BioSupply.FFFenterprises.com | (800) 843-7477

©2026 FFF Enterprises, Inc. All Rights Reserved. Property of FFF Enterprises, Inc.FL1284-PB Rev 083126